Construction and Characterization of purD Gene Deleted Brucella abortus

Muhammad Ilyas Riaz1, Masood Rabbani1*, Sohail Raza1, Ali Raza Awan2, Aleena Kokab1 and Iqra Nazir3

1Institute of Microbiology, University of Veterinary and Animal Sciences, Lahore, Pakistan;
2Institute of Biochemistry and Biotechnology, University of Veterinary and Animal Sciences, Lahore, Pakistan
3College of Agriculture, Department of Animal Sciences, Purdue University, West Lafayette, USA

ABSTRACT

Bovine brucellosis is an important zoonotic and contagious disease targeting humans, domestic and wild animals all over the globe resulting in significant economic losses therefore, disease mitigation and control measures are of pronounced significance. The two available vaccines of Brucella abortus in Pakistan, RB51, and S19 have many limitations in the light of residual virulence, induction of abortion, diagnostic interference, and human pathogenic potential. In this study, we have developed a Brucella abortus pUC19-K-UP-DN plasmid cassette for the construction of ΔpurD deleted mutant by deleting the purD gene which is responsible for de novo purine synthesis. For this, the pUC19-K-UP-DN plasmid cassette was initially constructed using pUC19, kanamycin, and purD upstream and downstream fragments. Then the cassette was electroporated into electro competent Brucella abortus RB51. The ΔpurD mutant was confirmed using PCR analysis. Afterward, the growth kinetics of the mutant was compared with parent RB51. The mutant bacterial growth significantly reduces (P< 0.05) as compared to the parent non-mutant mutant bacteria regain growth in enriched media. The results confirmed that the highly attenuated Brucella abortus ΔpurD mutant can be used successfully as a potential vaccine candidate for the control of bovine brucellosis.

INTRODUCTION

Brucellosis is an important zoonosis globally targeting both humans and livestock listed among the top-ranked bacterial problems in developing countries and it is positioned second among worldwide zoonotic problems by OIE (Iqbal et al., 2020; Manual, 2019). Every year more than 500,000 new human cases of brucellosis are reported by World Health Organization (Ezama et al., 2018). From a public health and zoonotic viewpoint, brucellosis is considered an occupational disease that mainly affects farm workers, butchers, slaughterhouse workers, and veterinarians (Park et al., 2018). According to published data, the first human brucellosis case in Pakistan was reported back in 1979 (Ali et al., 2018). Presently, higher disease cases were reported in Punjab province including hospital outdoor records showing 5.8-10.7% and 6.87-38.94% get infection via occupational exposure. After Punjab, Khyber Pakhtunkhwa province reported the highest number of cases ranging between 2-36.4% at different outdoor hospitals but is still recognized as one of the misdiagnosed and underreported human diseases in Pakistan (Mahmood et al., 2016). Brucellosis is linked adversely to livestock reproductive potential and production losses in the form of milk and meat (Akhtar et al., 2019). Infection with Brucella abortus leads to reproductive failure especially abortion in the last trimester of gestation and placentitis, infertility and metritis in females and epididymitis, orchitis, seminal vesiculitis, and sterility in males (Khan et al., 2021).

Due to these serious economic impacts and public health-associated risks substantial eradication programs for brucellosis have been implemented to prevent, control, and eliminate the disease in animals. Among all of these,
vaccination has been proven to be a crucial factor in the control and prevention of the disease. Vaccination with live attenuated \textit{Brucella abortus} strains such as rough strain RB51 and smooth strain 19 have been extensively used for years and have been proven against the prevention and control of disease in field conditions (Truong et al., 2016). However, these vaccines have several constraints in the light of antibiotic resistance, residual virulence, and diagnostic interference and are pathogenic to humans (Ashford et al., 2004).

Among different available vaccines, the RB51 rough vaccine strain of \textit{Brabortus} has been widely used in different countries including Pakistan for brucellosis control and it does not generate antibodies against the O-polysaccharide chain of smooth lipopolysaccharide of \textit{Br. abortus} which provides clear serological differentiation between vaccinated and infected animals giving it a notable advantage for its use in the control of disease (Schurig et al., 2002). However RB51 strain has some limitations because of its residual virulence and could be isolated from different animal body secretions including milk, vaginal fluid, and fetuses of vaccinated buffaloes and cows showing its substantial replication in vaccinated animals (Yazdi et al., 2009).

To overcome these limitations extensive efforts have been made to identify some accessory vaccine targets for the potential of live attenuated vaccines (Wang and Wu, 2013). In the present study, to improve the safety of the RB51 vaccine, we construct a more attenuated gene deleted mutant of RB51 by targeting the \textit{purD} (phosphoribosylamine-glycine ligase) gene which played a crucial role in the de novo purine nucleotide synthesis during its replication through site-directed mutagenesis.

**MATERIALS AND METHODS**

**Bacterial strain, its culturing, and identification**

\textit{Brucella abortus} RB51 (RB 51) was taken from Clinical Diagnostic Complex (CLC), UVAS and the entire work has been done by adopting strict biosafety practices recommended by Centers for Diseases Control and Prevention, Brucellosis Reference Guide, 2017 (Khurana et al., 2021). The bacteria was cultured in Tryptone Soy Agar (TSA, Oxoid Ltd, Basingstoke, UK) by inoculating 0.2 mL on agar plate supplemented with rifampicin antibiotic (250 μg/mL) and 1% fetal bovine serum (Gibco, Life Technologies Ltd, Paisley, UK) at 37°C in the incubator for 4-5 days under aerobic conditions (Saxena and Raj, 2018) and also on Tryptone Soy Broth (TSB, Oxoid Ltd, Basingstoke, UK) supplemented with rifampicin antibiotic (250 μg/mL) and 1% fetal bovine serum in shaking incubator at 150 rpm, 37°C overnight (Sergueev et al., 2017). The isolated colonies of RB51 were identified for the characteristic colony morphology, Gram staining and coccobacilli characteristics of \textit{Brucella abortus}. The final confirmation was done by PCR through amplification of IS711 repetitive region of the bacterial genome by using primers mentioned in Table I and bacterial DNA extraction was done using GF-1 Bacterial DNA Extraction Kit (Vivantis, Selangor Darul Ehsan, Malaysia) and PCR was performed by previously described method (O’Leary et al., 2006).

**Kanamycin amplification and insertion in pUC19**

The \textit{purD} gene deletion cassette (pUC19-K-UP-DN) was constructed by using commercially purchased pUC19 vector (Thermoscientific, Vilnius, Lithuania). Firstly, Kanamycin (KM) gene was amplified using pEP-kan (Raza et al., 2009) DNA as template through PCR by using its specific primers shown in Table I. The amplified product size of KM was confirmed on agarose gel and purified using the gel purification kit (Gene JET Gel Extraction, Thermoscientific, USA). The purified KM product and pUC19 plasmid was subjected to restriction enzyme digestion by using \textit{KpnI} (Thermoscientific, Vilnius, Lithuania) and \textit{BamHI} (Thermoscientific, Vilnius, Lithuania) restriction enzymes. The restriction enzyme digested pUC19 and KM were run on agarose gel and subjected to gel purification. Afterward, enzyme digested confirmed products of pUC19 and KM were ligated by using T4 DNA Ligase (Thermoscientific, Vilnius, Lithuania), and the ligated product was transformed into \textit{Escherichia coli} DH5α competent cells using the heat shock method. The positive KM clones were screened on KM supplemented Luria-Bertani (LB) agar plate and confirmed using restriction digest analysis and named pUC19-K.

**purD UP and DN stream sequence cloning**

\textit{purD} gene upstream (UP) and downstream (DN) sequences were amplified through PCR by using UP and DN specific primers shown in Table I and \textit{Br. abortus} DNA as a template. The amplified UP and DN PCR products were confirmed via agarose gel electrophoresis. The pUC19-K and UP PCR product were enzyme digested using \textit{KpnI} and \textit{EcoRI} (Thermoscientific, Vilnius, Lithuania) at 37°C. After 3 h the enzyme digested products were run on agarose gel and purified through gel purification kit. The purified products were ligated via T4 DNA ligase for overnight incubation at 4°C. The ligation mixture was transformed into competent \textit{E. coli} DH5α cells and plated on LB agar plate supplemented with KM (30μg/mL) for 24 h at 37°C. The positive clones were confirmed using restriction digest analysis and named ad pUC19-K-UP.
Table I. List of primers used in this study.

| Primer   | Name         | Sequence (5' to 3') | Product size (bp) | Target location         |
|----------|--------------|---------------------|-------------------|-------------------------|
| *Br. abortus* | B.A (F)     | GACGAACGGAATTTTTCCCATCCC   | 498               | IS711 genomic region    |
|          | B.A (R)     | TGCCGATCACCTAAGGGGCTTCTCAT |                   |                         |
| Kanamycin | KM (F)      | GCGGTACCTAGGGATAACAGGGTAATCGATTT (KpnI) | 1004              | KM                      |
|          | KM (R)      | CGGGATCCGCCAGTGTTACAACC (BamHI) |                   |                         |
| Upstream | UP (F)      | CGGAATTCTCCTGATCGACCAGATCATTAG (EcoR1) | 492               | purD upstream          |
|          | UP (R)      | CGGGTACCCATGCCTTGCTCCCT (KpnI) |                   |                         |
| Downstream | DN (F)    | GCGGATCCTGATCGGTTTATGTTTCAGGTTACATG (BamHI) | 482               | purD downstream        |
|          | DN (R)      | CGCTGCAGTCGCCGTCGTTCCGACCGTCACGT (PstI) |                   |                         |
| purD     | PD (F)      | AACTGCAGGATGAAAGTTCTGTTGATC | 1280              | Detecting purD         |
|          | PD (F)      | GCTCTAGAGTCAGCGATTAGCCTTCA |                   |                         |

Bold letter indicates sequence of restriction sites inserted.

The DN amplified product and pUC19-K-UP were enzyme digested using *Bam*HI and *Pst*I (Thermoscientific, Vilnius, Lithuania) at 37°C for 3 h. The enzyme digested products were run on agarose gel and purified through gel purification kit. Afterward, the purified products were ligated via T4 DNA ligase at 4°C for the overnight period. The ligation mixture was transformed into competent *E.coli* DH5α cells and screened on KM added LB agar plate at 37°C for 24 h. The positive clones were confirmed using restriction digest analysis and named as pUC19-K-UP-DN deletion cassette.

**Construction of ΔpurD mutant**

For the construction of *Br. abortus* ΔpurD mutant, the electro competent cells of RB51 were prepared by adopting the previously described method (McQuiston et al., 1995). The purD gene deletion cassette pUC19-K-UP-DN was electroporated into electrocompetent RB51 cells at 2.5 kV, 20 msee by using Gene Pulser Xcell™ (Biorad, California, USA) as per the protocol described earlier (Lalsiamthara et al., 2020). The purD gene deleted mutants were screened after 5 days on KM added TSA agar medium and further cultured on KM supplemented TSB media. Afterward, the ΔpurD mutant colonies were selected and confirmed by using PCR for *Br. abortus*, KM, and the purD gene deletion using published primers (Truong et al., 2015) mentioned in Table I.

**Phenotypic characterization and growth kinetics of ΔpurD mutant**

The growth kinetics and phenotypic characterization of the ΔpurD mutant was analyzed by developing a growth curve as described previously (Lalsiamthara et al., 2020). Briefly, a single colony of both ΔpurD mutant and parent RB51 were cultured in 5mL of TSB for 24 h in the shaking incubator at 37°C. A total of 200µL from 24 h broth culture was then inoculated in 19.8 mL TSB at 160 rpm shaking and 37°C for the period of 72 h. The ΔpurD mutant and parent RB51 strains were also subjected to growth analysis in purine supplemented TSB by adding 1mM adenine, 1mM guanine, 1mM hypoxanthine, and 0.05 mM thiamine (Sigma-Aldrich, Merck, Darmstadt, Germany) by adopting the previously described method (Truong et al., 2015) at 37°C with shaking for 72 h. The growth kinetics was checked by estimating the OD value at 600 nm in the ELISA reader at different time intervals. For future usage, the deleted mutant was stored by using Microbank Microbial Storage Veils (Pro-Lab Diagnostics, Richmond Hill, Canada) at -80°C as per manufacturer instructions.

**Statistical analysis and software used**

The data of the growth curve was analyzed by using the software GraphPad Prism 5. Two-way analysis of variance (ANOVA) test was applied for comparison of the ΔpurD mutant group with the RB51 group. The *P*-value < 0.05 was considered statistically significant.

**RESULTS**

*Br. abortus* colonies on TSA agar showed characteristics morphology of small, round, 1-2mm diameter, smooth margins with pale honey color and Gram staining confirms Gram-negative pink coccobacilli rods when observed under oil immersion lens at (100X). The molecular conformation via PCR showed amplicon size of the IS711 repetitive region (498 bp) on agarose gel electrophoresis.

The pUC19-K-UP-DN plasmid cassette was developed and confirmed as shown in Figure 1 by adopting the following scheme. The KM amplified sequence showed (1004 bp) size as shown in (Fig. 1B). The restriction enzyme digest analysis of pUC19-K transformed *E.coli* DH5α cells confirms two bands of (2686) bp (pUC19) and...
The ΔpurD deleted mutant showed characteristic small, circular, pale color colony morphology of *Br. abortus* on KM supplemented TSA plate. The colony PCR of ΔpurD deleted showed (498 bp) of *IS711* region for *Bracella abortus* (Fig. 2A), (986 bp) of KM (Fig. 2B), and absence of (1280 bp) purD gene ΔpurD mutant in comparison to parent RB51 strain (Fig. 2C).

The growth phenotype of ΔpurD deleted mutant

The growth kinetics of ΔpurD deleted mutant showed O.D values 0.052, 0.063, 0.158, 0.512 and 0.866 at 6, 12, 24, 48, and 72 h while RB51 showed O.D values 0.077, 0.344, 0.942, 1.512, and 1.364 in TSB culture media without purine bases supplementation. Therefore, the growth kinetics suggested that ΔpurD grows at a significantly reduced (*P* < 0.05) rate in comparison to parent strain over this period (Fig. 3A). As shown in (Fig. 3B) the ΔpurD deleted mutant showed reinstatement growth in adenine, guanine, thiamine, and hypoxanthine enriched TSB media showed O.D values 0.129, 0.374, 0.869, 1.207 and 1.398 and grows almost a similar rate showed O.D values 0.134, 0.418, 0.917, 1.218 and 1.417 at 6, 12, 24, 48, and 72 h in comparison to the parent RB51 strain.

DISCUSSION

*Brucellosis* is one of the foremost problems impacting both livestock and the human population globally because of its high zoonotic and infection potential reported 500,000...
annual cases exclusively in humans by the World Health Organization (Ezama et al., 2018). The most common approach adopted worldwide for disease mitigation and control is by application of live attenuated RB51 vaccinal strain to prevent bovine brucellosis (Truong et al., 2015). Although RB51 is considered very efficacious for disease prevention in vaccinated animals but also has many reported side effects in both animals and humans. (Arellano-Reynoso et al., 2004; Yazdi et al., 2009).

The molecular confirmation published in the previous study (Lalsiamthara et al., 2020). The PCR amplification and sequencing of the purD gene showed 398 bp product for wild RB51 strain, (1122 bp) KM, and (1150 bp) ΔpurD mutant in comparison to the wild S19 strain in the study results were also observed in the deleted ΔS19 Br. abortus, (986 bp) KM, and no band in the ΔpurD mutant while (1280 bp) product was seen in parenteral RB51 bacterial strain which supported previous study (Truong et al., 2015).

In our study, we also determined the growth kinetics of the ΔpurD mutant in comparison to the parent strain to monitor the effect of purine pathway synthesis in enriched and non-enriched purine TSB media while comparing with the parent strain over different time points confirming the inability to de novo purine biosynthesis. The parent RB51 strain showed an elevated growth pattern as compared to the ΔpurD mutant in purine non-enriched media over different time duration. When appropriate supplementation with adenine, guanine, thymine, and hypoxanthine purine bases was done in growth media the ΔpurD mutant displayed the restoration of growth and grew at an almost similar rate to the parent RB51 strain confirming the re-establishment of de novo purine biosynthesis pathway in the deleted mutant which is correlated with the previous study published by (Truong et al., 2015). Similar phenotypic growth kinetics results were also observed in the Br. abortus deleted AS19 mutant in comparison to the wild S19 strain in the study published by (Lalsiamthara et al., 2020).

CONCLUSION

The current study findings concluded that the purD gene is required by bacteria for the de novo purine synthesis pathway and a key factor for RB51 virulence in the host. This is the first study on Brucella gene deletion reported from Pakistan which will be very beneficial for identifying new vaccine candidate genes for more attenuated, safe, and effective indigenous Br. abortus vaccine development for brucellosis mitigation and control in the livestock sector both in local and international settings. The ΔpurD deleted mutant was originally constructed from the RB51 strain so further studies are needed to check its attenuation status and immunogenic potential in the animal model in
comparison to RB51.

Statement of conflict of interest

The authors have declared no conflict of interest.

REFERENCES

Akhtar, R., Iqbal, M.Z., Ullah, A., Ali, M.M., Zahid, B., Ijaz, M., Ullah, A., and Taseer, M.S.A., 2019. Comparative association of slc11a1 (Nramp1) gene with susceptibility and resistance to brucellosis in various cattle and buffaloes breeds of Pakistan. *Pak. Vet. J.*, 39: 612-614. https://doi.org/10.29261/pakvetj/2019.091

Alcantara, R.B., Read, R.D., Valderas, M.W., Brown, T.D., and Roop, R.M., 2004. Intact purine biosynthesis pathways are required for wild-type virulence of *Brucella abortus* 2308 in the BALB/c mouse model. *Infect. Immun.*, 72: 4911-4917. https://doi.org/10.1128/IAI.72.8.4911-4917.2004

Ali, S., Nawaz, Z., Akhter, A., Aslam, R., Zahoor, M.A., and Ashraf, M., 2018. Epidemiological investigation of human brucellosis in Pakistan. *Jundishapur J. Microbiol.*, 11: 1-5. https://doi.org/10.5812/jjm.61764

Arellano-Reynoso, B., Díaz-Aparicio, E., Leal-Hernández, M., Hernández, L., and Gorvel, J-P., 2004. Intracellular trafficking study of a RB51 *B. abortus* vaccinal strain isolated from cow milk. *Vet. Microbiol.*, 98: 307-312. https://doi.org/10.1016/j.vetmic.2003.10.024

Ashford, D.A., Di Pietra, J., Lingappa, J., Woods, C., Noll, H., Neville, B., Weyant, R., Bragg, S.L., Spiegel, R.A., and Tapper, J., 2004. Adverse events in humans associated with accidental exposure to the livestock brucellosis vaccine RB51. *Vaccine*, 22: 3435-3439. https://doi.org/10.1016/j.vaccine.2004.02.041

Drazek, E.S., Houng, H., Crawford, R.M., Hadfield, T.L., Hoover, D.L. and Warren, R.L., 1995. Deletion of purE attenuates Brucella melitensis 16M for growth in human monocyte-derived macrophages. *Infect. Immun.*, 63: 3297-3301. https://doi.org/10.1128/iai.63.9.3297-3301.1995

Ezama, A., Gonzalez, J.P., Majalija, S., and Bajunirwe, F., 2018. Assessing short evolution brucellosis in a highly brucella endemic cattle keeping population of Western Uganda: A complementary use of Rose Bengal test and IgM rapid diagnostic test. *BMC Publ. Hlth.*, 18: 1-5. https://doi.org/10.1186/s12889-018-5228-9

Iqbal, M., Fatmi, Z., and Khan, M.A., 2020. Brucellosis in Pakistan: A neglected zoonotic disease. *J. Pak. med. Assoc.*, 70: 1625. https://doi.org/10.5455/JPMA.24139

Khan, I., Ali, S., Hussain, R., Raza, A., Younus, M., Khan, N., and Faheem, M., 2021. Serosurvey and potential risk factors of brucellosis in dairy cattle in peri-urban production system in Punjab, Pakistan. *Pak. Vet. J.*, 10: 459-462.

Khurana, S.K., Sehrawat, A., Tiwari, R., Prasad, M., Gulati, B., Shabbir, M.Z., Chhabra, R., Karthik, K., Patel, S.K., and Pathak, M., 2021. Bovine brucellosis. A comprehensive review. *Vet. Quart.*, 41: 61-88. https://doi.org/10.1080/01652176.2020.1868616

Kim, S., Watarai, M., Kondo, Y., Erdenebaatar, J., Makino, S.I., and Shirahata, T., 2003. Isolation and characterization of mini-Tn 5 Km2 insertion mutants of *Brucella abortus* deficient in internalization and intracellular growth in HeLa cells. *Infect. Immun.*, 71: 3020-3027. https://doi.org/10.1128/IAI.71.6.3020-3027.2003

Lalsiamthara, J., Kaur, G., Gogia, N., Ali, S.A., Goswami, T.K., and Chaudhuri, P., 2020. *Brucella abortus* S19 rfbD mutant is highly attenuated, DIVA enable and confers protection against virulent challenge in mice. *Biologicals*, 63: 62-67. https://doi.org/10.1016/j.jbiologicals.2019.11.005

Lalsiamthara, J., Kaur, G., Gogia, N., Ali, S.A., Goswami, T.K., and Chaudhuri, P., 2020. *Brucella abortus* S19 rfbD mutant is highly attenuated, DIVA enable and confers protection against virulent challenge in mice. *Int. Biol.*, 63: 62-67.

Mahmood, R., Ali, T., Waheed, U., Asif, M., and Khan, Q.M., 2016. Application of serum based PCR and fluorescence polarization assay for diagnosis of brucellosis among people occupationally at risk to disease. *Int. J. Agric. Biol.*, 18: 311-318. https://doi.org/10.17957/IJAB/15.0099

Manual, O.T., 2019. *Brucellosis* (*Brucella abortus*, *B. melitensis* and *B. suis*)(infection with *B. abortus*, *B. melitensis* and *B. suis*). Manual of diagnostic tests and vaccines for terrestrial animals. OIE, World Organisation for Animal Health.

McQuiston, J.R., Schurig, G.G., Siriranganathan, N., and Boyle, S.M., 1995. Transformation of *Brucella* species with suicide and broad host-range plasmids. In: *Electroporation protocols for microorganisms.* (Springer), pp. 143-148. https://doi.org/10.1385/0-89603-310-4:143

O’Leary, S., Sheahan, M. and Sweeney, T., 2006. *Brucella abortus* detection by PCR assay in blood, milk and lymph tissue of serologically positive
cows. *Res. Vet. Sci.*, **81**: 170-176. https://doi.org/10.1016/j.rvsc.2005.12.001

Park, J.H., Hwang, S.D., Acharya, D., Lee, S.H., Hwang, K.J., Yoo, S.J., and Lee, K., 2018. Seroreactivity and risk factors associated with *Coxiella burnetii* infection among cattle slaughterhouse workers in South Korea. *Int. J. environ. Res. Publ. Hlth.*, **15**: 2264. https://doi.org/10.3390/ijerph15102264

Raza, S., Deng, M., Shahin, F., Yang, K., Hu, C., Chen, Y., Chen, H., and Guo, A., 2016. A bovine herpesvirus 1 pUL51 deletion mutant shows impaired viral growth in vitro and reduced virulence in rabbits. *Oncotarget*, **7**: 12235. https://doi.org/10.18632/oncotarget.7771

Saxena, H.M., and Raj, S., 2018. A novel immunotherapy of Brucellosis in cows monitored non invasively through a specific biomarker. *PLoS Negl. Trop. Dis.*, **12**: e0006393. https://doi.org/10.1371/journal.pntd.0006393

Schurig, G.G., Sriranganathan, N., and Corbel, M.J., 2002. Brucellosis vaccines: past, present and future. *Vet. Microbiol.*, **90**: 479-496. https://doi.org/10.1016/S0378-1135(02)00255-9

Sergueev, K.V., Filippov, A.A., and Nikolich, M.P., 2017. Highly sensitive bacteriophage-based detection of *Brucella abortus* in mixed culture and spiked blood. *Viruses*, **9**:144. https://doi.org/10.3390/v9060144

Truong, Q.L., Cho, Y., Barate, A.K., Kim, S., Watarai, M., and Hahn, T.W., 2015. Mutation of *purD* and *purF* genes further attenuates *Brucella abortus* strain RB51. *Microb. Pathog.*, **79**: 1-7. https://doi.org/10.1016/j.micpath.2014.12.003

Truong, Q.L., Cho, Y., Park, S., Kim, K., and Hahn, T.W., 2016. *Brucella abortus ΔcydCΔcydD* and *ΔcydCA purD* double-mutants are highly attenuated and confer long-term protective immunity against virulent *Brucella abortus*. *Vaccine*, **34**: 237-244. https://doi.org/10.1016/j.vaccine.2015.11.030

Wang, Z., and Wu, Q., 2013. Research progress in live attenuated *Brucella* vaccine development. *Curr. Pharm. Biotechnol.*, **14**: 887-896. https://doi.org/10.2174/1389201014666131226123016

Yazdi, H.S., Kafi, M., Haghkhah, M., Tamadon, A., Behrozikhah, A., and Ghane, M., 2009. Abortions in pregnant dairy cows after vaccination with *Brucella abortus* strain RB51. *Vet. Rec.*, **165**: 570. https://doi.org/10.1136/vr.165.19.570